Report of immune monitoring of prostate cancer patients undergoing T- cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)

Prostate

Volumn 35, Issue 2, 1998, Pages 144-151

  Salgaller, Michael L ^a   Lodge, Patricia A ^a   McLean, Joanne G ^a   Tjoa, Ben A ^b   Loftus, Douglas J ^c   Ragde, Haakon ^b   Kenny, Gerald M ^b   Rogers, Mary ^b   Boynton, Alton L ^b   Murphy, Gerald P ^b  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^b NORTHWEST HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dendritic cells; Immunotherapy; Monitoring; Phase II trial; Prostate cancer; T cell

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; MEMBRANE ANTIGEN; PEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOLOGICAL MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SKIN TEST; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENES, MHC CLASS I; GLUTAMATE CARBOXYPEPTIDASE II; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0031895770     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980501)35:2<144::AID-PROS8>3.0.CO;2-J     Document Type: Article

References (40)

1. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
2. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP: Dendritric cells in antitumor immune responses. Cell Immunol 1996;170:111-119.
3. Grabbe S, Beissert S, Schwarz T, Granstein RD: Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol Today 1995;16:117-121.
4. + cytotoxic T lymphocytes by dendritic cells. J Exp Med 1987;166: 182-194.
5. + helper T cells. J Exp Med 1990;171:1315-1332.
6. Rammensee H, Friede T, Stevanovic S: MHC ligand and peptide motifs: First listing. Immunogenetics 1996;41:178-228.
7. Akdas A, Turkeri L, Alican Y, Simsek F, Akogiu T: Human leukocyte antigen subtype analysis in patients with advanced adenocarcinoma of the prostate. Prostate 1994;24:111-113.
8. Tjoa B, Erickson S, Barren R III, Ragde H, Kenny G, Boynton A, Murphy G: In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995;27:63-69.
9. Chen Y, Sidney J, Southwood S, Cox AL, Sakaguchi K, Henderson RA, Appella E, Hunt DF, Sette A, Engelhard VH: Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J Immunol 1994;2874-2981.
10. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP: Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997; 32:272-278.
11. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
12. Ishizaka S, Kimoto M, Araki T: Detection of soluble T cell receptor-releasing T cells by ELISPOT assay. J Immunoassay 1995; 16:97-113.
13. Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM, Zavala F: Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 1995;181:45-54.
14. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA: Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-4757.
15. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJM, Oseroff C, Yuan L, Ruppert J, Sidney J, del Guercio M, Southwood S, Kubo RT, Chesnut RW, Grey HM, Chisari FV: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586-5592.
16. Jones RC, Kelley M, Gupta RK, Nizze JA, Yee R, Leplatois Z, Qi K, Stern S, Morton DL: Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model. Ann Surg Oncol 1996;3:437-445.
17. Morton DL, Foshag LJ, Hoon DSB: Prolongation of survival in metastatic melanoma after reactive specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216: 463-482.
18. Barth A, Hoon DSB, Foshag LJ, Nizze JA, Famatiga E, Okun E, Morton DL: Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994;54:3342-3345.
19. McCune CC, O'Donnell RW, Marquis DM, Sahasrabudhe PM: Renal-cell carcinoma treated by vaccines for active specific immunotherapy: A correlation of survival with skin testing by autologous tumor. Cancer Immunol Immunother 1990;32:62-66.
20. Bystryn J, Oratz R, Roses D, Harris M, Henn M, Lew R: Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992;69:1157-1164.
21. Abbas AK, Lichtman AH, Pober JS: "Cellular and Molecular Immunology," Philadelphia: W.B. Saunders Co., 1994.
22. Singluff CL Jr: Tumor antigens and tumor vaccines: Peptides as immunogens. Semin Surg Oncol 1996;12:446-453.
23. Reynolds SR, Oratz R, Shapiro RL, Vukmanovic S, Bystryn J-C: A polyvalent melanoma vaccine induced MAGE-3 and MART-1/Melan-A specific CD8+ T cell responses that correlate with clinical outcome [abstract]. In: "International Symposium on Cancer Vaccines; 1996 Oct 7-9," New York: Cancer Research Institute Publications, 1989:60.
24. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
25. Weidmann E, Trucco M, Whiteside TL: Relevance of the T cell receptor for immunotherapy of cancer. Cancer Immunol Immunother 1994;39:1-14.
26. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-1798.
27. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-5616.
28. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, Ochoa AC: Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995;1:1327-1335.
29. Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K: Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix. J Cell Biol 1986;102:688-696.
30. Chapman PB, Lonberg M, Houghton AN: Light chain variants of an IgG3 anti-GD3 mononuclear antibody and the relationship between avidity, effector functions, tumor targeting, and anti-tumor activity. Cancer Res 1990;50:1503-1509.
31. Miller K, Abeles G, Oratz R, Zeleniuch-Jacquotte A, Cui J, Roses DF, Harris MN, Bystryn J: Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 1995;75:495-502.
32. Hoon DSB, Yuzuki D, Hayashida M, Morton DL: Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 1995;154:730-737.
33. McCaffrey M, Yao T, Williams L, Livingston PO, Houghton AN, Chapman PB: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 1996;2:679-686.
34. Mascart-Lemone F, Gerard M, Libin M, Crusiaux A, Franchioly P, Lambrechts A, Goldman M, Clumeck N: Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. J Infect Dis 1995; 172:1253-1260.
35. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, Bennick JR: Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-272.
36. Germain RN, Margulies DH: The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993;11:403-450.
37. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL: Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996;2:1263-1274.
38. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J, Vivier E, Anderson P, Kiessling R: Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993;53:5610-5612.
39. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D: Interleukin 10 production by human melanoma. Clin Cancer Res 1996;2:1383-1390.
40. Maffezzini M, Simonato A, Fortis C: Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (a-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 1996;28:282-286.